Data-Star Sample Record
A N
97119294
A U
Farci-P, Mandas-A, Coiana-A, Lai-M-E, Desmet-V, Van-Eyken-P, Gobi-Y, Caruso-L, Scaccabarozzi-S,
et-al.
T I
Treatment of chronic hepatitis D with interferon alfa-2a.
S O
New-England-Journal-of-Medicine 330 (2). 1994. 88-94. ISSN 0028-4793.
I N
Hepatitis Viruses Section, Lab Infectious Diseases, Natl Inst Allergy Infectious Diseases, Natl Inst
Health, Build 7, Rm 200, 9000 Rockville Pike, Bethesda, MD 20892, USA.
L G
EN.
Y R
94.
K W RESEARCH ARTICLE; HUMAN; INTERFERON-ALPHA-2A; ANTIVIRAL-DRUG; HORMONE-DRUG;
ALANINE AMINOTRANSFERASE; VIRAL RNA; POST-TREATMENT RELAPSE.
C C
1 0 0 0 6 * Clinical Biochemistry; General Methods and Applications;
1 0 8 0 8 * Enzymes-Physiological Studies;
1 2 5 0 8 * Pathology, General and Miscellaneous-Inflammation and Inflammatory Disease;
1 2 5 1 2 * Pathology, General and Miscellaneous-Therapy (1971- );
1 3 0 1 2 * Metabolism-Proteins, Peptides and Amino Acids;
1 3 0 1 4 * Metabolism-Nucleic Acids, Purines and Pyrimidines;
1 4 0 0 6 * Digestive System-Pathology;
1 5 0 0 8 * Blood, Blood-Forming Organs and Body Fluids-Lymphatic Tissue and Reticuloendothelial
System;
1 7 0 0 2 * Endocrine System-General;
2 2 0 0 5 * Pharmacology-Clinical Pharmacology (1972- );
2 2 0 1 4 * Pharmacology-Digestive System;
2 2 0 1 6 * Pharmacology-Endocrine System;
3 6 0 0 6 * Medical and Clinical Microbiology-Virology;
3 8 5 0 6 * Chemotherapy-Antiviral Agents.
1 0 0 6 2
Biochemical Studies-Nucleic Acids, Purines and Pyrimidines;
1 0 0 6 4
Biochemical Studies-Proteins, Peptides and Amino Acids;
1 0 0 6 8
Biochemical Studies-Carbohydrates;
3 1 5 0 0
Genetics of Bacteria and Viruses.
B C
0 2 6 0 0
Animal Viruses-General (1993- );
8 6 2 1 5
Hominidae.
S T
MICROORGANISMS#, VIRUSES#, ANIMALS#, CHORDATES#, VERTEBRATES#, MAMMALS#,
PRIMATES#, HUMANS#.
A B
Background and Methods. Chronic hepatitis D is a severe and rapidly progressive liver disease for
which no therapy has been proved effective. To evaluate the efficacy of treatment with interferon, we
studied 42 patients with chronic hepatitis D who were randomly assigned to receive either 9 million
or 3 million units of recombinant interferon alfa-2a (three times a week for 48 weeks) or no
treatment. Results. By the end of the treatment period, serum alanine aminotransferase values had
become normal in 10 of 14 patients receiving 9 million units (71 percent), as compared with 4 of 14
treated with 3 million units (29 percent, P = 0.029) and 1 of 13 untreated controls (8 percent,
P = 0.001). Seven patients treated with the higher dose of interferon (50 percent) had a complete
response (normal levels of alanine aminotransferase and no detectable serum hepatitis delta virus
(HDV) RNA), as compared with three of those who received the lower dose (21 percent, P = 0.118),
and none of the controls (P = 0.004). Treatment with 9 million units of interferon was associated
with a marked improvement in the histologic findings (reduced periportal necrosis and portal and
lobular inflammation), whereas in the untreated controls there was considerable histologic
deterioration. In 5 of the 10 patients treated with 9 million units of interferon whose alanine
aminotransferase values became normal, the biochemical responses persisted for up to 4 years
(mean, 39 months), but the effects of treatment on viral replication were not sustained. In contrast,
none of those who received 3 million units and none of the untreated controls had a sustained
biochemical or virologic response. Conclusions. In about half the patients with chronic hepatitis D
treated with high doses of interferon alfa-2a (9 million units three times a week for 48 weeks), the
serum alanine aminotransferase level becomes normal, HDV RNA becomes undetectable in serum,
and there is histologic improvement. However, a relapse is common after treatment has been stopped.
S F
Biological Abstracts Vol. 097 Iss. 006 Ref. 069169.
S a m p l e R e c o r d s b y S e a r c h S y s t e m
2 7
